TCF
NEUTRALTheracryf Plc Appoints New Nominated Adviser and Joint Broker
The clinical stage drug development company has appointed a new nominated adviser and joint broker.
Theracryf
0.2460GBX
-3.53%
Market Cap
5.24M
Volume
6.42M
183% of avg
P/E Ratio
-0.00
EPS (TTM)
-0.5
Beta
1.27
Day Range
0.2300p - 0.2460p
52 Week Range
0.2000p0.2460p1.2500p
0.2460p
Upcoming Events
Early 2026
Expected start of SFX-01 study in glioblastoma patients
High Impact Event
Late Q4 2026
End of current cash runway
High Impact Event
TCF
NEUTRALTheraCryf Plc Hosts Ox-1 Investor Presentation
The clinical stage therapeutics company is hosting an investor presentation on its Ox-1 addiction programme.
TCF
NEUTRALTheraCryf Extends Cash Runway to Q4 2026, Focuses on Orexin-1 Antagonist Program
The clinical-stage drug developer has extended its cash runway and sharpened focus on its orexin-1 antagonist program for addiction treatment, while maintaining progress in other areas.
TCF
NEUTRALTheraCryf Plc Announces Full Year Results and Ox-1 Presentation
The clinical-stage therapeutics company announces the release of its full year results and a presentation on its Ox-1 addiction programme.
TCF
NEUTRALTheracryf Plc Announces Change in Shareholding
The healthcare company has announced a transfer of a 19.67% shareholding from Tracarta Limited to its 51% owned subsidiary, Northern Standard Limited.
TCF
NEUTRALTheraCryf Director Increases Stake
The healthcare company has announced a change in one of its director's shareholdings.
TCF
NEUTRALTheracryf Plc Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
TCF
NEUTRALTheracryf signs Master Service Agreement for Ox-1 programme development
The clinical stage drug development company has signed an agreement with contract research organisation Pharmaron to progress development of its Orexin-1 addiction programme.
TCF
NEUTRALTheraCryf Plc Announces Board Changes and Option Grants
The clinical-stage drug development company announces a new non-executive director appointment and grants of options to employees and management.
TCF
NEUTRALTheracryf Plc to Host Investor Webinar
The clinical stage therapeutics company is hosting an investor webinar to discuss its plans for its Ox-1 addiction and SFX-01 glioblastoma programmes.